Mithra Pharmaceuticals SA
Mithra was founded in 1999 by François Fornieri, a pharmacist and entrepreneur who wanted to create new solutions for women's health issues. Mithra is headquartered in Liège, Wallonia, and has a market cap of about 500 million euros as of May 2023.
Mithra has two complementary pipelines focused on women's health: an innovative Estetrol-based platform and a portfolio of Complex Therapeutics. Estetrol (E4) is a unique estrogen produced by the human fetus during pregnancy that has its own mode of action and benefits for contraception and menopause. Mithra has developed several products based on E4, such as Estelle, a combined oral contraceptive pill; Donesta, a hormone therapy for menopausal symptoms; and PeriNesta, a hormone therapy for perimenopausal symptoms.
Mithra also has a portfolio of Complex Therapeutics, which are generic or hybrid versions of existing drugs that have improved features or formulations. These include Myring, a vaginal ring for contraception; Tibelia, a hormone therapy for menopause; and Zoreline, an implant for prostate cancer and endometriosis.
Mithra has received several awards and recognitions for its innovation and performance, such as the Belgian Biotech Award in 2019, the Trends Gazelles Award in 2020 and 2021, and the Euronext Tech Leader Award in 2021. Mithra also has a strong commitment to environmental, social, and governance (ESG) principles, as reflected in its annual report and ESG strategy.
Foundation: 1999
Headquarters: Wallonia, Belgium
Website: https://www.mithra.com/en/
